Close Menu

NEW YORK (GenomeWeb) — CancerLinQ has entered into an agreement with Tempus and Precision HealthAI to accelerate development and delivery of high-quality, deidentified clinical databases, CancerLinQ said yesterday.

The databases are intended for use by CancerLinQ, a non-profit subsidiary of the American Society of Clinical Oncology, as well as its oncologist subscribers, partners, and the broader cancer community. They will be made available through the core CancerLinQ quality improvement platform and the organization's CancerLinQ Discovery service.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.